Relationship between toxicity and CDA status
| Toxicity, n (%) . | ||
|---|---|---|
| CDA activity, U/mg . | ||
| <2 (PM) (n = 28) . | ≥2 (EM + UM) (n = 30) . | |
| Severe | 18 (64) | 7 (23) |
| Digestive | 10 (36) | 2 (7) |
| Cutaneous | 3 (11) | 1 (3) |
| Other* | 5 (16) | 4 (13) |
| Death resulting from toxicity | 3 (11) | 0 (0) |
| Toxicity, n (%) . | ||
|---|---|---|
| CDA activity, U/mg . | ||
| <2 (PM) (n = 28) . | ≥2 (EM + UM) (n = 30) . | |
| Severe | 18 (64) | 7 (23) |
| Digestive | 10 (36) | 2 (7) |
| Cutaneous | 3 (11) | 1 (3) |
| Other* | 5 (16) | 4 (13) |
| Death resulting from toxicity | 3 (11) | 0 (0) |
Distribution in severe toxicities (grade ≥3 per Common Terminology Criteria for Adverse Events) in patients with CDA PM status (<2 U/mg) or non-PM status (CDA ≥2 U/mg).
Others toxicities were: 4 cases of sepsis and 1 hyperthermia (CDA <2 U/mg) and 2 cases of sepsis, 1 renal impairment, and 1 hyperthermia (CDA ≥2 U/mg).